<DOC>
	<DOCNO>NCT00350961</DOCNO>
	<brief_summary>In Denmark approximately 200 new case cholangiocarcinoma diagnose every year . No standard treatment exist patient advanced cholangiocarcinoma , improve systemic treatment need . Duplets gemcitabine , oxaliplatin capecitabine evaluate various cancer several different regimen well tolerate active , especially upper gastrointestinal cancer , exocrine pancreatic cancer non-small cell lung cancer . The triplet combination agent study , triplet combination gemcitabine , oxaliplatin 5-FU infusion evaluate phase I study . Bi-weekly combination gemcitabine oxaliplatin proven active tolerable warrant study . In addition , fix dose rate infusion gemcitabine show interesting ability mononuclear cell accumulate gemcitabine triphosphate therapy seem saturable . We propose phase I-II study bi-weekly schedule gemcitabine , oxaliplatin capecitabine . This regimen could feasible out-patients set . The phase I part standard dose escalation study patient solid tumor . In phase II part recommend dose studied patient advance cholangiocarcinoma .</brief_summary>
	<brief_title>Gemcitabine , Oxaliplatin Capecitabine Patients With Advanced Cholangiocarcinoma</brief_title>
	<detailed_description>Design Open , non-randomized phase I/II study . Purpose : Phase I part To find MTD RFTD combination gemcitabine , oxaliplatin capecitabine . Dose Escalating Schedule Dose level Dose Gemcitabine 10 mg/m2/min 600-1000 mg/m2 day 1 14 Capecitabine p.o . x 2 daily . 1000-1250 mg/m2 day 1-7 14-21 Oxaliplatin 60-80 mg/m2day 1 14 Drugs : G C O Level 1 600 1000 60 Level 2 800 1000 60 Level 3 1000 1000 60 Level 4 1000 1250 60 Level 5 1000 1250 80 Level 6 1200 1250 80 Start level : Level 1 , 3 patient per level Phase II part The primary endpoint objective response rate The secondary endpoint toxicity , response duration time progression . Treatment : Gemcitabine Gemcitabine give intravenously day 1 14 fix dose rate 10 mg/m2/min . Oxaliplatin Oxaliplatin give intravenously day 1 14 2 hour infusion . Capecitabine Capecitabine give orally administer tablet 150 mg 500 mg . The dose administer twice daily 12 hour interval , morning evening late 30 minute meal .</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically proven intra extrahepatic cholangiocarcinoma , papilla Vater gallbladder carcinoma . PS 02 Age 1875 Life expectancy &gt; 12 week Normal bone marrow function ( neutrophile &gt; 1,5 x 109/l platelet &gt; 100 x 109/l ) Bilirubin &lt; 1,5 x UNL Transaminases &lt; 3 x UNL Normal renal function , CrEDTA clearance &gt; 50 ml/min No chemotherapy , radiotherapy immunotherapy 4 week prior inclusion No known DPDdeficiency No neuropathy No uncontrolled , severe concurrent medical disease Signed informed consent Chemotherapy , radiotherapy immunotherapy 4 week prior inclusion Experimental therapy &lt; 8 week prior inclusion Uncontrolled , severe concurrent medical disease Prior malignancy last 5 year , except nonmelanoma skin cancer carcinoma situ cervix uterus . Allergy gemcitabine , oxaliplatin capecitabine Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Cholangiocarcinoma</keyword>
	<keyword>Fixed dose rate</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Capecitabine</keyword>
</DOC>